|
US2531011A
(en)
*
|
1949-01-22 |
1950-11-21 |
Sterling Drug Inc |
3-chloro-9-[2-(2-hydroxyethylamino)-ethylamino] acridine and method for its production
|
|
US3232945A
(en)
|
1962-08-13 |
1966-02-01 |
S E Massengill Company |
7,8,9,10-tetrahalo-6h-cyclohepta-(b)-quinolines
|
|
US3458525A
(en)
*
|
1966-07-01 |
1969-07-29 |
American Home Prod |
Spiro(indoline-3,2'-thiazolidine)-2-one and derivatives
|
|
US4534899A
(en)
|
1981-07-20 |
1985-08-13 |
Lipid Specialties, Inc. |
Synthetic phospholipid compounds
|
|
US4426330A
(en)
|
1981-07-20 |
1984-01-17 |
Lipid Specialties, Inc. |
Synthetic phospholipid compounds
|
|
US4902505A
(en)
|
1986-07-30 |
1990-02-20 |
Alkermes |
Chimeric peptides for neuropeptide delivery through the blood-brain barrier
|
|
EP0268871A1
(en)
|
1986-10-31 |
1988-06-01 |
Sumitomo Pharmaceuticals Company, Limited |
Quinoline derivatives
|
|
WO1988007852A1
(en)
|
1987-04-06 |
1988-10-20 |
Innovative Therapeutics Corporation |
Liposome entrapped magnesium
|
|
WO1988007851A1
(en)
|
1987-04-06 |
1988-10-20 |
Innovative Therapeutics Corporation |
Liposome entrapped n-methyl-d-aspartate receptor blockers
|
|
US5284876A
(en)
|
1988-02-26 |
1994-02-08 |
Neuromedica, Inc. |
Method of treating tardive dyskinesia using dopaminergic agents of prodrugs of therapeutic agents
|
|
US4939174A
(en)
|
1988-02-26 |
1990-07-03 |
Shashoua Victor E |
Appetite suppression with dopamine-fatty acid conjugates
|
|
US4933324A
(en)
|
1988-02-26 |
1990-06-12 |
Shashoua Victor E |
Fatty acid-neuroactive drug conjugate as a prodrug
|
|
US5354844A
(en)
|
1989-03-16 |
1994-10-11 |
Boehringer Ingelheim International Gmbh |
Protein-polycation conjugates
|
|
US5108921A
(en)
|
1989-04-03 |
1992-04-28 |
Purdue Research Foundation |
Method for enhanced transmembrane transport of exogenous molecules
|
|
US5019400A
(en)
|
1989-05-01 |
1991-05-28 |
Enzytech, Inc. |
Very low temperature casting of controlled release microspheres
|
|
US5227170A
(en)
|
1989-06-22 |
1993-07-13 |
Vestar, Inc. |
Encapsulation process
|
|
US4999430A
(en)
*
|
1989-07-31 |
1991-03-12 |
Warner-Lambert Company |
Derivatives of 1,2,3,4-tetrahydro-9-acrisinamine
|
|
US5672683A
(en)
|
1989-09-07 |
1997-09-30 |
Alkermes, Inc. |
Transferrin neuropharmaceutical agent fusion protein
|
|
US5154924A
(en)
|
1989-09-07 |
1992-10-13 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
|
|
WO1993010819A1
(en)
|
1991-11-26 |
1993-06-10 |
Alkermes, Inc. |
Process for the preparation of transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
|
|
US5182107A
(en)
|
1989-09-07 |
1993-01-26 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
|
|
CA2025907A1
(en)
|
1989-09-21 |
1991-03-22 |
Franklin D. Collins |
Method of transporting compositions across the blood brain barrier
|
|
US5013556A
(en)
|
1989-10-20 |
1991-05-07 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
|
US5356633A
(en)
|
1989-10-20 |
1994-10-18 |
Liposome Technology, Inc. |
Method of treatment of inflamed tissues
|
|
US5527528A
(en)
|
1989-10-20 |
1996-06-18 |
Sequus Pharmaceuticals, Inc. |
Solid-tumor treatment method
|
|
US5271961A
(en)
|
1989-11-06 |
1993-12-21 |
Alkermes Controlled Therapeutics, Inc. |
Method for producing protein microspheres
|
|
CA2029497C
(en)
*
|
1989-11-08 |
2002-06-04 |
Kunihiro Ninomiya (Deceased) |
4-acylaminopyridine derivative
|
|
JPH03236315A
(ja)
|
1989-12-05 |
1991-10-22 |
Nippon Oil & Fats Co Ltd |
抗精神病薬
|
|
US5469854A
(en)
|
1989-12-22 |
1995-11-28 |
Imarx Pharmaceutical Corp. |
Methods of preparing gas-filled liposomes
|
|
US5580575A
(en)
|
1989-12-22 |
1996-12-03 |
Imarx Pharmaceutical Corp. |
Therapeutic drug delivery systems
|
|
US5264618A
(en)
|
1990-04-19 |
1993-11-23 |
Vical, Inc. |
Cationic lipids for intracellular delivery of biologically active molecules
|
|
US5268164A
(en)
|
1990-04-23 |
1993-12-07 |
Alkermes, Inc. |
Increasing blood-brain barrier permeability with permeabilizer peptides
|
|
US5112596A
(en)
|
1990-04-23 |
1992-05-12 |
Alkermes, Inc. |
Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
|
|
US5109921A
(en)
|
1991-04-29 |
1992-05-05 |
Halliburton Company |
Controlled weak point for wireline cable
|
|
JP3220180B2
(ja)
|
1991-05-23 |
2001-10-22 |
三菱化学株式会社 |
薬剤含有タンパク質結合リポソーム
|
|
NZ244306A
(en)
|
1991-09-30 |
1995-07-26 |
Boehringer Ingelheim Int |
Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
|
|
US5521291A
(en)
|
1991-09-30 |
1996-05-28 |
Boehringer Ingelheim International, Gmbh |
Conjugates for introducing nucleic acid into higher eucaryotic cells
|
|
US5260308A
(en)
|
1991-11-06 |
1993-11-09 |
Mayo Foundation For Medical Education And Research |
Method to increase permeability of the blood-nerve/brain barriers to proteins
|
|
WO1993017668A1
(en)
|
1992-03-12 |
1993-09-16 |
Alkermes Controlled Therapeutics, Inc. |
Controlled release acth containing microspheres
|
|
AU677216B2
(en)
|
1992-07-27 |
1997-04-17 |
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
Targeting of liposomes to the blood-brain barrier
|
|
US5583020A
(en)
|
1992-11-24 |
1996-12-10 |
Ribozyme Pharmaceuticals, Inc. |
Permeability enhancers for negatively charged polynucleotides
|
|
JP3351476B2
(ja)
|
1993-01-22 |
2002-11-25 |
三菱化学株式会社 |
リン脂質誘導体及びそれを含有するリポソーム
|
|
US5395619A
(en)
|
1993-03-03 |
1995-03-07 |
Liposome Technology, Inc. |
Lipid-polymer conjugates and liposomes
|
|
US5462854A
(en)
|
1993-04-19 |
1995-10-31 |
Beckman Instruments, Inc. |
Inverse linkage oligonucleotides for chemical and enzymatic processes
|
|
US5534259A
(en)
|
1993-07-08 |
1996-07-09 |
Liposome Technology, Inc. |
Polymer compound and coated particle composition
|
|
US5543158A
(en)
|
1993-07-23 |
1996-08-06 |
Massachusetts Institute Of Technology |
Biodegradable injectable nanoparticles
|
|
US5417978A
(en)
|
1993-07-29 |
1995-05-23 |
Board Of Regents, The University Of Texas System |
Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use
|
|
US5595756A
(en)
|
1993-12-22 |
1997-01-21 |
Inex Pharmaceuticals Corporation |
Liposomal compositions for enhanced retention of bioactive agents
|
|
US5543152A
(en)
|
1994-06-20 |
1996-08-06 |
Inex Pharmaceuticals Corporation |
Sphingosomes for enhanced drug delivery
|
|
US5591721A
(en)
|
1994-10-25 |
1997-01-07 |
Hybridon, Inc. |
Method of down-regulating gene expression
|
|
US5512295A
(en)
|
1994-11-10 |
1996-04-30 |
The Board Of Trustees Of The Leland Stanford Junior University |
Synthetic liposomes for enhanced uptake and delivery
|
|
EP1012331B1
(en)
|
1997-07-01 |
2006-03-29 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for the delivery of oligonucleotides via the alimentary canal
|
|
US6235769B1
(en)
|
1997-07-03 |
2001-05-22 |
Sugen, Inc. |
Methods of preventing and treating neurological disorders with compounds that modulate the function of the C-RET receptor protein tyrosine kinase
|
|
JP2002537343A
(ja)
|
1999-02-23 |
2002-11-05 |
アイシス・ファーマシューティカルス・インコーポレーテッド |
多重粒子製剤
|
|
US6287860B1
(en)
|
2000-01-20 |
2001-09-11 |
Isis Pharmaceuticals, Inc. |
Antisense inhibition of MEKK2 expression
|
|
FI20000480A0
(fi)
*
|
2000-03-01 |
2000-03-01 |
Orion Yhtymae Oyj |
Kinoliini- ja naftaleenijohdannaisia alfa-2 antagonisteina
|
|
US7001905B2
(en)
*
|
2000-03-15 |
2006-02-21 |
Warner-Lambert Company |
Substituted diarylamines as MEK inhibitors
|
|
AU2003248893A1
(en)
*
|
2002-07-09 |
2004-01-23 |
Alpha Research Group, L.L.C. |
Compositions and methods for the treatment of parkinson's disease and tardive dyskinesias
|
|
US20040034019A1
(en)
*
|
2002-08-08 |
2004-02-19 |
Ronald Tomlinson |
Piperazine and piperidine derivatives
|
|
EP1551809A1
(en)
|
2002-10-09 |
2005-07-13 |
Pfizer Products Inc. |
Pyrazole compounds for treatment of neurodegenerative disorders
|
|
JP2007506741A
(ja)
*
|
2003-09-23 |
2007-03-22 |
メルク エンド カムパニー インコーポレーテッド |
向代謝性グルタミン酸受容体のピラゾール系調節剤
|
|
AU2005245470A1
(en)
|
2004-05-20 |
2005-12-01 |
Foldrx Pharmaceuticals, Inc. |
2-((hetero) aryl)-benzoxazole compounds and derivatives, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
|
|
WO2006094237A2
(en)
*
|
2005-03-03 |
2006-09-08 |
Sirtris Pharmaceuticals, Inc. |
Acridine and quinoline dervatives as sirtuin modulators
|
|
GB0505086D0
(en)
*
|
2005-03-11 |
2005-04-20 |
Glaxo Group Ltd |
Compounds
|
|
DE202005008426U1
(de)
|
2005-05-31 |
2005-09-15 |
Ricon Sieb Und Foerdertechnik |
Fördervorrichtung mit Fördertuch
|
|
JP5388574B2
(ja)
|
2005-05-31 |
2014-01-15 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
イオンチャネルのモジュレーターとして有用なヘテロ環式類
|
|
US8686045B2
(en)
|
2005-06-08 |
2014-04-01 |
The University Of North Carolina At Chapel Hill |
Methods of facilitating neural cell survival using non-peptide and peptide BDNF neurotrophin mimetics
|
|
WO2008010984A2
(en)
*
|
2006-07-17 |
2008-01-24 |
The Trustees Of The University Of Pennsylvania |
Acridine activation of p53 and uses thereof
|
|
US7605265B2
(en)
*
|
2007-01-22 |
2009-10-20 |
Biotechnology Research Corporation Ltd. |
Heterodimers and methods of using them
|
|
US20080234267A1
(en)
|
2007-03-20 |
2008-09-25 |
Karen Elizabeth Lackey |
Compounds and Methods of Treatment
|
|
US8420670B2
(en)
*
|
2007-08-22 |
2013-04-16 |
Abbott Laboratories |
4-benzylaminoquinolines, pharmaceutical compositions containing them, and their use in therapy
|
|
US7863295B2
(en)
*
|
2008-02-12 |
2011-01-04 |
Children's Medical Center Corporation |
Treatments for neuropathy
|
|
US20110045100A1
(en)
|
2008-03-05 |
2011-02-24 |
Georgetown University |
Antimalarial Quinolines and Methods of Use Thereof
|
|
US10867398B2
(en)
|
2017-11-21 |
2020-12-15 |
Reliance Core Consulting LLC |
Methods, systems, apparatuses and devices for facilitating motion analysis in an environment
|